Zealthy Review: What Its GLP-1 Program Documents—and What the Evidence Does Not Establish

A telehealth program can offer access to a medication without having evidence that its own service produces the results associated with that medication. That distinction matters when reading Zealthy’s weight-management advertising. Its pages describe medical review, semaglutide and tirzepatide options, coaching, insurance assistance and online follow-up. They also mix introductory offers, conditional medication prices and membership charges. Understanding the program requires separating three questions: what Zealthy promises to deliver, what a particular medicine has been studied to do, and what the enrollment agreement requires.

This review examines Zealthy’s public documentation consulted October 19, 2026. It is not an independent verification of pharmacy licenses, clinician credentials, availability or treatment outcomes. The documentation supports describing Zealthy as a GLP-1 telehealth provider, but not treating its marketing as a clinical performance report. Its strongest disclosures concern membership services and billing responsibilities. Its weaker areas include the precise compounded products offered, state availability, response times and the relationship between advertised medication minimums and the total amount a patient would pay.

At a glance

Ordinary membership: Zealthy lists a typical membership price of $135 per month, including a medical provider and dedicated coach; medication and pharmacy fulfillment generally cost extra.
Sources: [8] [5]
Conflicting introductory offers: The pricing page presents both a $49 first month with an $86 discount and a separate $39 starting offer. The documentation does not establish which offer applies at enrollment.
Sources: [8]
Conditional medication minimums: Advertised prices as low as $151 per month for semaglutide and $216 per month for tirzepatide are tied to purchasing three-month supplies, not unconditional monthly treatment prices.
Sources: [8]
Compounded-product disclosure: Zealthy says its compounded drugs come from a state-licensed sterile compounding pharmacy and acknowledges that compounded GLP-1 medications are not FDA approved.
Sources: [9]
Ongoing financial responsibility: The subscription renews automatically until properly canceled. Cancellation generally preserves access through the paid cycle but does not create a prorated refund.
Sources: [5]

Start with the business, not the outcome claim

Zealthy’s subscription policy identifies FitRX, LLC doing business as Zealthy as the entity offering subscription-based telemedicine services. It also describes a provider network that includes Bruno Health, P.A. and affiliated medical groups, with Zealthy providing administrative and management services. Elsewhere, the contact block uses Zealthy, Inc. The consulted documentation does not explain the relationship between those corporate names. That is a documentation gap, not evidence that care is or is not delivered appropriately.

The broader Zealthy website advertises virtual primary care, mental health and metabolic health services, with or without insurance. Its weight-management offering specifically describes GLP-1 medication access, a medical provider, a coach and insurance coordination. These are documented commercial offerings. They do not independently establish professional licensure, successful insurance authorization, medication availability or a particular clinical result. Our guide to what provider documents can prove explains why those are separate verification questions.

The pricing page also discloses that members sharing their stories received compensation. Those stories may illustrate an advertised experience, but they are not a controlled assessment of the service. The consulted documentation does not establish a Zealthy-specific average weight change, discontinuation rate or adverse-event rate. A fair reading therefore gives the company credit for describing its service while resisting the leap from individual stories or medication research to measured program performance.

Different documents answer different questions
Documentation	What it supports	What it does not establish
Service pages	Advertised medications, coaching and online access	Verified outcomes or individual availability
Pricing page	Published offers and their stated conditions	A universal all-in treatment price
Subscription policy	Renewal, payment and cancellation responsibilities	A guarantee of prescribing or coverage
Compounded-drug disclosure	Zealthy’s stated pharmacy sourcing and nonapproval disclosure	Independent license verification or product equivalence
Medication trials	Findings for the studied products and populations	Zealthy-specific performance

Sources: [5] [4] [8]

The medication name is only the beginning

Zealthy advertises semaglutide and tirzepatide through insurance-supported and out-of-pocket pathways. Its branded list includes Ozempic, Wegovy, Zepbound and Mounjaro. The company distinguishes products it describes as approved for weight loss from those approved for type 2 diabetes that may be prescribed off-label at a healthcare provider’s discretion. That disclosure should not be read as making every listed product interchangeable, universally covered or appropriate for every person seeking weight management.

For compounded treatment, Zealthy says its drugs are prepared by a state-licensed sterile compounding pharmacy and explicitly acknowledges that compounded GLP-1 medications are not FDA approved. The pharmacy is not identified by name in the consulted material, and no independently checked license information is available here. Treatment cards advertise injections, but the documentation does not fully specify each compounded product’s concentration, complete formulation, presentation or route. Ingredient names alone cannot close those gaps.

FDA explains that compounded preparations do not undergo its premarket review for safety, effectiveness and quality. FDA recommends their use when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not demonstrate clinical inequivalence, nor does a shared ingredient name establish equivalence. The distinction between approved medicines and compounded preparations is therefore central to evaluating Zealthy’s options—not a technical footnote.

Sources: [9] [6] [1]

Clinical research does not measure Zealthy’s performance

STEP 1 illustrates both the value and the boundary of medication evidence. This randomized trial enrolled 1,961 adults with obesity, or overweight plus a weight-related condition, without diabetes. Over 68 weeks, studied subcutaneous semaglutide at 2.4 mg weekly produced mean weight change of minus 14.9%, versus minus 2.4% with placebo; both groups received lifestyle intervention. That dose identifies the study arm only. It is not a treatment instruction or a description of what Zealthy would prescribe.

Gastrointestinal events led to discontinuation in 4.5% of semaglutide participants and 0.8% of placebo participants. Novo Nordisk funded the trial. These details belong beside the efficacy result because tolerability, study population and sponsorship help readers interpret the finding. The trial did not test Zealthy’s service, its compounded preparations, different routes or individual outcomes. Our STEP 1 evidence guide provides a fuller explanation of those boundaries.

The same discipline applies to Zealthy’s coaching and monitoring claims. The company describes support, but the consulted material does not isolate how much that support contributes to outcomes. NIDDK explains that medication accompanies healthy eating and physical activity, and that follow-up concerns response and tolerability. A program’s access features may be useful, but their existence is not equivalent to a published evaluation showing that the program reliably delivers a particular weight change.

Sources: [3] [2] [6]

What intake and continuing care actually promise

The advertised process starts with medical intake, followed by a Zealthy provider reviewing treatment options such as semaglutide or tirzepatide. A coach helps develop a personalized weight-management plan, and the pages invite members to message their provider and coach. The program also advertises online refill management and progress tracking without office visits. These statements describe a remote service pathway, but they do not specify a guaranteed clinical-review deadline or mandatory appointment schedule.

Zealthy’s BMI chart labels 24.9 or below as outside the program, 25.0–26.9 as case-by-case, and higher categories as likely. Crucially, accompanying text says people with BMI 25–29 may require further review for weight-related medical issues, and that the prescriber decides after considering the individual health profile. The chart does not guarantee approval. The consulted material also does not establish a minimum age, complete exclusion criteria or required laboratory testing.

Continuing support includes advertised unlimited coach messaging, nutrition and fitness work, and plan adjustments as needed. Treatment cards also advertise supplies and 24/7 access to licensed medical providers at no extra cost. Those are provider claims, not independently verified staffing or response-time findings. The policy excludes emergency care and monitoring urgent communications. Readers should distinguish the ability to send a message at any hour from a promised immediate clinical response or a defined follow-up cadence.

Sources: [9] [6] [5]

The published prices describe several different purchases

Zealthy lists a typical membership price of $135 per month, including a medical provider for GLP-1 management when appropriate, refills and prescription updates, plus a dedicated coach. The policy says ordinary membership does not inherently include medication or pharmacy fulfillment. It identifies exceptions: Semaglutide + Doctor and Tirzepatide + Doctor include those costs with membership. The consulted documentation does not establish each bundled plan’s total price or whether the advertised medication minimums correspond to those bundles.

The same pricing page presents a $49 first month after an $86 limited-time discount and a separate $39 starting offer. The latter lists an online assessment, provider review, prescription if appropriate, insurance-coordinator support and transmission to a selected pharmacy. Neither figure should silently replace the other. Before paying, a prospective member needs the applicable introductory charge, its duration, the next charge and the medication component confirmed together. The public page does not resolve that inconsistency.

For three-month purchases, Zealthy advertises 20% off compounded medication, with prices as low as $151 per month for semaglutide or $216 for tirzepatide. It also advertises 20% off the next two membership months in that context. These are conditional minimums, not universal all-in prices; semaglutide’s insurance labeling is also inconsistent across the material. Discounted quarterly, semiannual and annual memberships are advertised without amounts. The policy separately warns that some members may need multiple membership months for continuity of care.

Sources: [8] [5]

Insurance assistance is not coverage evidence

The branded-medication offer lists Ozempic, Wegovy, Zepbound and Mounjaro as low as $25 per month with insurance. Zealthy says its coordination team helps maximize coverage. Neither statement guarantees that a particular plan will cover a particular prescription. The consulted material does not identify all accepted insurers, savings-card requirements, government-insurance conditions or authorization timelines. NIDDK likewise notes that weight-management medication coverage varies by plan. A low advertised copay is therefore a possible outcome, not a universal entry price.

Membership coverage is a separate issue. Zealthy’s policy says its membership fee is not a covered benefit under most insurance or healthcare benefit arrangements, including its discussion of HSA/FSA plans, and warns that the member may remain responsible. That statement does not settle tax treatment or confirm practical card acceptance. The policy also allows other charges, including missed appointments, late rescheduling, prescriptions, delivery and recommended diagnostic testing. Published inclusions should be reconciled with the specific selected plan.

Availability claims need similar restraint. A treatment card’s “In Stock” language coexists with warnings that branded products may face shortages, waits exceeding 30 days and refill difficulties that create treatment gaps. These disclosures do not tell a reader which product is available locally today. Insurance acceptance for a consultation, approval of a prescription claim and actual pharmacy supply are different checkpoints. Zealthy’s documentation supports asking about all three rather than assuming one resolves the others.

Sources: [6] [5] [8] [2]

Pharmacy and delivery responsibilities remain partly unresolved

For compounded GLP-1s, the pricing page says shipment occurs one to four days after prescription. That is a dispatch statement, not a delivery deadline or a promise about how quickly intake will be reviewed. The documentation does not specify the carrier, packaging, refrigeration arrangements or how a three-month supply is distributed. It also does not identify the dispensing or compounding pharmacy by name. Those missing details limit what can be concluded about the complete fulfillment pathway.

FDA advises not using an injectable GLP-1 product that arrives warm or with insufficient refrigeration, and contacting the provider or dispensing pharmacy. FDA also reports errors measuring or administering compounded medications, some associated with hospitalization; instructions should be clarified with the prescriber or pharmacist rather than reconstructed from an article. These are general regulatory concerns, not documented Zealthy-specific incidents. Our guide to delivery and cold-chain claims explains why dispatch speed alone cannot answer a product-condition question.

The financial policy adds a separate delivery risk: when the carrier provides proof of delivery, Zealthy says it will not refund the medication, and a replacement order carries a new charge. Its New York contact address does not establish nationwide GLP-1 availability. The consulted pages leave state coverage unconfirmed. Zealthy advertises free iOS and Android apps and publishes 877-870-0323 as a contact number, but neither feature resolves pharmacy identity, state eligibility or shipment-condition questions.

Sources: [8] [9] [5] [4] [1]

Renewal and refund terms outlast the introductory offer

The policy authorizes automatic billing from the initial payment through subsequent renewal periods until cancellation under its terms. Charges may continue even when services are unused. Although the pricing page says monthly charges occur on the same day as the first charge, the policy warns billing may not occur on exactly the same date each month. Promotional fees eventually revert to the full nonpromotional rate, and free trials automatically become paid memberships unless canceled.

Cancellation begins in the patient profile through “manage membership,” then “manage your plan,” followed by the cancellation flow. The policy requires cancellation before renewal to avoid the next charge. Access generally continues until the current billing cycle ends, without a prorated refund except stated or legally required exceptions. A separate trial provision allows a refund for an erroneous membership charge when cancellation occurred at least 36 hours before the trial ended. That is a specific exception, not a general refund promise.

Consultations, provider visits and membership charges are described as nonrefundable. Medication becomes nonreturnable and nonrefundable once prescribed and filled by the partner pharmacy; another cancellation passage refers to shipment, leaving some ambiguity about the operative boundary. The separate refund page reserves refunds for processing errors and asks members to contact Zealthy about them. Cancellation should therefore be understood as stopping future renewal under the policy—not automatically reversing a current payment or an already progressing medication order.

Sources: [5] [8] [7]

Questions & answers

Does Zealthy’s $135 membership include my medication?

Ordinarily, no. The policy separates membership from medication and pharmacy fulfillment. It specifically says Semaglutide + Doctor and Tirzepatide + Doctor include those components, but the consulted pages do not establish each bundle’s total price. Ask for the exact plan name and an itemized first and renewal charge rather than adding together offers that may describe different purchases.

Sources: [5] [8]

Should I expect to pay $39 or $49 to start?

The pricing page contains both offers, so the public documentation does not resolve that question. The $49 offer is described as a discounted first membership month; the $39 offer lists assessment, review, prescribing if appropriate and insurance support. Obtain the applicable offer’s duration and subsequent charges before authorizing payment. Neither introductory amount establishes the cost of medication.

Sources: [8] [5]

Does Zealthy guarantee a prescription if I meet its BMI chart?

No. Zealthy expressly says approval depends on a prescriber’s review of the individual health profile. Its chart includes case-by-case consideration, and accompanying text calls for additional review of weight-related conditions in the BMI 25–29 range. It is an intake guide, not a diagnosis, prescription guarantee or complete description of the program’s clinical criteria.

Sources: [9]

Can I identify Zealthy’s compounded pharmacy before enrolling?

The consulted documentation says Zealthy uses a state-licensed sterile compounding pharmacy but does not name it or provide independently verified license details. Ask which pharmacy would prepare and dispense your specific prescription, and request the product’s complete formulation and presentation. The public material does not support assuming that every compounded option has the same specifications.

Sources: [9]

How quickly will Zealthy treatment arrive?

The published compounded-drug claim is shipment one to four days after prescription, not arrival within that period. Clinical review time, transit time and delivery conditions are not established. For branded products, Zealthy warns of possible waits exceeding 30 days and refill difficulties. A useful pre-enrollment question is which timeline applies to the exact product and pharmacy channel being considered.

Sources: [8]

How do I stop renewal, and will I get money back?

Use the patient-profile cancellation flow through “manage membership” and “manage your plan,” and complete cancellation before renewal. The policy generally preserves access through the paid cycle without a prorated refund. Medication, consultation and membership refund restrictions remain separate. Processing errors have a stated exception; canceling by itself does not establish entitlement to repayment of an existing charge.

Sources: [5] [7]

Our assessment

Zealthy documents a recognizable remote weight-management service: medical intake, prescribing consideration, coaching, insurance coordination and ongoing online support. Its explicit disclosure that compounded GLP-1s are not FDA approved is important, as is its distinction between ordinary membership and medication-inclusive bundles. Those strengths do not resolve conflicting introductory prices, conditional medication minimums, unidentified pharmacy sourcing or unspecified response and delivery arrangements. Clinical trial findings support conclusions about the studied medication regimens, not Zealthy’s program performance. The most useful next step is documentary clarification: obtain the exact product, pharmacy, plan inclusions, first and renewal charges, applicable state availability and follow-up arrangements in writing. Evaluate those answers alongside the restrictive refund policy, rather than treating a low advertised starting price or a medication trial result as a complete description of the service.

Visit Zealthy’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Zealthy Review: What Its GLP-1 Program Documents—and What the Evidence Does Not Establish

At a glance

01Start with the business, not the outcome claim

02The medication name is only the beginning

03Clinical research does not measure Zealthy’s performance

04What intake and continuing care actually promise

05The published prices describe several different purchases

06Insurance assistance is not coverage evidence

07Pharmacy and delivery responsibilities remain partly unresolved

08Renewal and refund terms outlast the introductory offer